Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALECNASDAQ:IMVTNASDAQ:KRYSNASDAQ:KYMRNASDAQ:SGMO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALECAlector$1.52+5.7%$1.35$0.87▼$6.78$152.59M0.74834,030 shs105,136 shsIMVTImmunovant$16.83+2.5%$15.35$12.72▼$34.47$2.88B0.631.22 million shs93,703 shsKRYSKrystal Biotech$140.74+0.7%$137.47$122.80▼$219.34$4.07B0.67286,189 shs16,623 shsKYMRKymera Therapeutics$43.34-1.1%$38.66$19.45▼$53.27$2.84B2.18631,528 shs42,924 shsSGMOSangamo Therapeutics$0.51+0.2%$0.54$0.31▼$3.18$119.85M1.239.00 million shs153,554 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALECAlector-2.37%+2.86%-3.36%+52.82%-67.20%IMVTImmunovant-2.29%+2.63%-2.09%+23.37%-38.93%KRYSKrystal Biotech-2.29%+1.66%+2.04%-11.94%-24.19%KYMRKymera Therapeutics-2.23%+0.39%-8.00%+108.12%+44.83%SGMOSangamo Therapeutics-4.51%-5.45%-3.43%-18.48%+58.70%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALECAlector3.8061 of 5 stars3.13.00.04.51.12.50.0IMVTImmunovant1.3863 of 5 stars3.52.00.00.00.01.70.0KRYSKrystal Biotech4.4776 of 5 stars3.51.00.04.72.22.51.9KYMRKymera Therapeutics3.3282 of 5 stars4.51.00.00.03.72.50.0SGMOSangamo Therapeutics2.7187 of 5 stars3.34.00.00.02.40.80.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALECAlector 2.14Hold$4.00162.81% UpsideIMVTImmunovant 2.90Moderate Buy$38.33127.78% UpsideKRYSKrystal Biotech 3.00Buy$211.1350.01% UpsideKYMRKymera Therapeutics 3.00Buy$59.1136.38% UpsideSGMOSangamo Therapeutics 2.67Moderate Buy$4.50777.19% UpsideCurrent Analyst Ratings BreakdownLatest SGMO, KRYS, KYMR, IMVT, and ALEC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/3/2025KYMRKymera TherapeuticsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$70.006/27/2025KYMRKymera TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$56.00 ➝ $53.006/26/2025KYMRKymera TherapeuticsBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$59.006/26/2025KYMRKymera TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$57.00 ➝ $53.006/26/2025KYMRKymera TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$54.00 ➝ $60.006/25/2025KYMRKymera TherapeuticsJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetBuy ➝ Buy$64.006/24/2025KRYSKrystal BiotechHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$240.006/24/2025SGMOSangamo TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.006/3/2025KYMRKymera TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$60.006/3/2025KYMRKymera TherapeuticsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$57.00 ➝ $64.006/3/2025KYMRKymera TherapeuticsB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$38.00 ➝ $60.00(Data available from 7/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALECAlector$100.56M1.51N/AN/A$1.29 per share1.18IMVTImmunovantN/AN/AN/AN/A$4.16 per shareN/AKRYSKrystal Biotech$290.52M14.00$4.56 per share30.85$32.90 per share4.28KYMRKymera Therapeutics$47.07M59.97N/AN/A$12.90 per share3.36SGMOSangamo Therapeutics$57.80M2.07N/AN/A$0.11 per share4.66Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALECAlector-$119.05M-$1.26N/AN/AN/A-139.74%-100.58%-25.15%8/6/2025 (Estimated)IMVTImmunovant-$413.84M-$2.74N/AN/AN/AN/A-80.60%-71.89%8/5/2025 (Estimated)KRYSKrystal Biotech$89.16M$4.1633.8513.96N/A37.17%14.64%13.28%8/4/2025 (Estimated)KYMRKymera Therapeutics-$223.86M-$3.10N/AN/AN/A-409.07%-30.11%-25.65%8/6/2025 (Estimated)SGMOSangamo Therapeutics-$97.94M-$0.39N/AN/AN/A-124.61%-345.98%-79.86%8/5/2025 (Estimated)Latest SGMO, KRYS, KYMR, IMVT, and ALEC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/5/2025Q1 2026IMVTImmunovant-$0.69N/AN/AN/AN/AN/A8/5/2025Q2 2025SGMOSangamo Therapeutics-$0.07N/AN/AN/A$31.68 millionN/A8/4/2025Q2 2025KRYSKrystal Biotech$1.20N/AN/AN/A$95.42 millionN/A5/29/2025Q4 2025IMVTImmunovant-$0.72-$0.64+$0.08-$0.64N/A$0.16 million5/12/2025Q1 2025SGMOSangamo Therapeutics-$0.11-$0.14-$0.03-$0.14$7.90 million$6.44 million5/9/2025Q1 2025KYMRKymera Therapeutics-$0.92-$0.82+$0.10-$0.82$11.38 million$22.10 million5/6/2025Q1 2025KRYSKrystal Biotech$1.38$1.20-$0.18$1.20$98.66 million$88.18 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALECAlectorN/AN/AN/AN/AN/AIMVTImmunovantN/AN/AN/AN/AN/AKRYSKrystal BiotechN/AN/AN/AN/AN/AKYMRKymera TherapeuticsN/AN/AN/AN/AN/ASGMOSangamo TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALECAlector0.103.343.34IMVTImmunovantN/A11.1611.16KRYSKrystal BiotechN/A9.659.27KYMRKymera TherapeuticsN/A8.498.49SGMOSangamo TherapeuticsN/A0.760.76Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALECAlector85.83%IMVTImmunovant47.08%KRYSKrystal Biotech86.29%KYMRKymera TherapeuticsN/ASGMOSangamo Therapeutics56.93%Insider OwnershipCompanyInsider OwnershipALECAlector9.10%IMVTImmunovant5.90%KRYSKrystal Biotech13.70%KYMRKymera Therapeutics16.01%SGMOSangamo Therapeutics4.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALECAlector27099.99 million90.89 millionOptionableIMVTImmunovant120170.92 million160.84 millionOptionableKRYSKrystal Biotech21028.90 million24.94 millionOptionableKYMRKymera Therapeutics17065.12 million54.69 millionOptionableSGMOSangamo Therapeutics480233.17 million223.61 millionOptionableSGMO, KRYS, KYMR, IMVT, and ALEC HeadlinesRecent News About These CompaniesH.C. Wainwright Reaffirms Buy Rating on Sangamo After Promising Gene Therapy DataJuly 3, 2025 | msn.comSGMO - Sangamo Therapeutics Inc Trailing Returns - MorningstarJuly 2, 2025 | morningstar.comMSangamo Therapeutics Announces Positive Topline Results From Registrational STAAR Study in Fabry Disease - MorningstarJune 25, 2025 | morningstar.comMSangamo Therapeutics Announces Positive Topline Results From Registrational STAAR Study in Fabry Disease - Business WireJune 25, 2025 | businesswire.comSangamo cues up Fabry gene therapy filing on STAAR dataJune 25, 2025 | pharmaphorum.comPSangamo Therapeutics, Inc.: Sangamo Therapeutics Announces Positive Topline Results From Registrational STAAR Study in Fabry DiseaseJune 24, 2025 | finanznachrichten.deSangamo preps FDA application for Fabry gene therapy on heels of phase 1/2 registrational dataJune 24, 2025 | fiercebiotech.comFSangamo rises after trial data for Fabry disease therapyJune 24, 2025 | msn.comSangamo Therapeutics (NASDAQ:SGMO) Given "Buy" Rating at HC WainwrightJune 24, 2025 | marketbeat.comSangamo Therapeutics Announces Positive Topline Results From Registrational STAAR Study in Fabry DiseaseJune 24, 2025 | businesswire.comSangamo Therapeutics, Inc. (NASDAQ:SGMO) Given Average Rating of "Moderate Buy" by BrokeragesJune 24, 2025 | marketbeat.comH.C. Wainwright Maintains Buy Rating on Sangamo Therapeutics (SGMO)May 31, 2025 | insidermonkey.comSangamo Therapeutics, Inc. (SGMO) Q1 2025 Earnings Call TranscriptMay 12, 2025 | seekingalpha.comSangamo Therapeutics Postpones First Quarter 2025 Conference Call to Later the Same DayMay 12, 2025 | finance.yahoo.comSangamo Therapeutics (SGMO) Reports Q1 Loss, Misses Revenue EstimatesMay 12, 2025 | zacks.comSangamo Therapeutics Reports Recent Business Highlights and First Quarter 2025 Financial ResultsMay 12, 2025 | businesswire.comSangamo Therapeutics Announces Pricing of $23.0 Million Underwritten OfferingMay 12, 2025 | businesswire.comSangamo Therapeutics Q1 2025 Earnings PreviewMay 12, 2025 | msn.comWhy Sangamo Therapeutics, Inc.’s (SGMO) Stock Is Up 5.70%May 10, 2025 | aaii.comASangamo Therapeutics Sets Sights on 2026 BLA Filing for Fabry Disease Gene TherapyMay 7, 2025 | precisionmedicineonline.comPSangamo Therapeutics Announces Important Derisking Milestones in Pathway to Anticipated BLA Submission for ST-920 in Fabry DiseaseMay 7, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWhy BigBear.ai Could Rally 100% and Catch Palantir SoonBy Gabriel Osorio-Mazilli | June 30, 2025View Why BigBear.ai Could Rally 100% and Catch Palantir Soon3 Defense Leaders Set to Gain From Rising Military SpendBy Chris Markoch | July 5, 2025View 3 Defense Leaders Set to Gain From Rising Military SpendIPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBy Dan Schmidt | June 20, 2025View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBigBear.ai Poised to Benefit as Palantir Dominates AI DefenseBy Gabriel Osorio-Mazilli | June 23, 2025View BigBear.ai Poised to Benefit as Palantir Dominates AI DefenseAnalysts Can't Get Enough of These Little-Known Biopharma StocksBy Nathan Reiff | June 12, 2025View Analysts Can't Get Enough of These Little-Known Biopharma StocksSGMO, KRYS, KYMR, IMVT, and ALEC Company DescriptionsAlector NASDAQ:ALEC$1.52 +0.08 (+5.69%) As of 10:42 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.Immunovant NASDAQ:IMVT$16.83 +0.41 (+2.49%) As of 10:42 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.Krystal Biotech NASDAQ:KRYS$140.74 +1.00 (+0.72%) As of 10:42 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.Kymera Therapeutics NASDAQ:KYMR$43.34 -0.47 (-1.06%) As of 10:42 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.Sangamo Therapeutics NASDAQ:SGMO$0.51 +0.00 (+0.23%) As of 10:42 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease. Its preclinical development products focus on CAR-Treg cell therapies for autoimmune disorders and genome engineering for neurological diseases. Sangamo Therapeutics, Inc. has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; and California Institute for Regenerative Medicine. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was incorporated in 1995 and is headquartered in Richmond, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas CoreWeave's $9 Billion Power Play for Core Scientific Micron Insiders Sell But Investors Should Buy, Buy, Buy Believe the Hype? Can SoFi Maintain Its 3-Month Rally? Could Dutch Bros Dethrone Starbucks? Why Investors Are Perking Up ExxonMobil: Limited Risk and Lots of Reward With This Oil Play Why Centene Stock Dropped 40% — And Whether It's a Buy Now D-Wave Is Rising Again Despite Dilution—What’s the Deal? Datadog Joins S&P 500, Triggering a New Wave of Upside Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.